Pictured: Facade of Sanofi's headquarters in France/iStock, HJBC

图为赛诺菲（Sanofi）法国总部正面/HJBC伊斯托克（iStock）

Sanofi has launched a sweeping restructuring initiative in its U.S. vaccines commercial operations, which will include an undisclosed number of layoffs, according to reporting by Endpoints News on Thursday.

据Endpoints News周四报道，赛诺菲已在其美国疫苗商业运营中启动了一项全面的重组计划，其中将包括未披露的裁员人数。

“We are continuously adapting to the evolving U.S. vaccines market to better support our customers and patients. These changes are aimed at optimizing our commercial structure for greater efficiency and effectiveness,” a company spokesperson told Endpoints.

“我们正在不断适应不断发展的美国疫苗市场，以更好地支持我们的客户和患者。这些变化旨在优化我们的商业结构，以提高效率和有效性，”该公司发言人告诉Endpoints。

Though the spokesperson declined to reveal details about the operations overhaul, including its timeline, scope and the number of employees that will be terminated, they revealed that the changes are part of Sanofi’s push to implement “a streamlined strategic sales structure.”

尽管这位发言人拒绝透露有关运营大修的细节，包括时间表、范围和将被解雇的员工人数，但他们透露，这些变化是赛诺菲推动实施“精简战略销售结构”的一部分

Sanofi has other openings within the company and the affected employees will have “opportunities to apply for the new positions,” according to the spokesperson.

该发言人表示，赛诺菲在公司内部还有其他职位空缺，受影响的员工将“有机会申请新职位”。

This latest round of layoffs comes after Sanofi announced last week that it would divest Amunix Pharmaceuticals, an immuno-oncology company. The move will eliminate 100 jobs from a San Francisco site, which will take effect on June 3, 2024. Sanofi acquired Amunix for $1 billion in December 2021.

赛诺菲上周宣布将剥离免疫肿瘤公司Amunix Pharmaceuticals，这是赛诺菲最近一轮裁员。这一举措将在2024年6月3日生效，届时旧金山的一个网站将减少100个工作岗位。2021年12月，赛诺菲以10亿美元收购了Amunix。

Earlier this month, Sanofi also announced a full pipeline reprioritization initiative, which would likewise involve the termination of an unspecified number of jobs.

本月早些时候，赛诺菲还宣布了一项全面的管道重新优先化计划，同样涉及终止数量不详的工作。

The restructuring is part of CEO Paul Hudson’s efforts to win back investor confidence after the pharma in October 2023 dropped its previously announced 32% operating profit margin target for 2025. At the time, Sanofi said the decision was made to “focus on long-term profitability.” Investors were not convinced.

该公司首席执行官保罗·哈德森（PaulHudson）于2023年10月下调了此前宣布的2025年32%的营业利润率目标，此次重组是该公司努力夺回投资者信心的一部分。赛诺菲当时表示，这一决定是为了“关注长期盈利能力”。投资者对此并不信服。

The news sent the pharma’s shares plummeting 15% and wiped around $21 billion off its market value..

该消息导致该制药公司股价暴跌15%，市值缩水约210亿美元。。

In December 2023, under mounting pressure to recapture the market’s favor, Sanofi held an R&D event for investors where it touted 12 pipeline assets that could reach blockbuster status in the coming years.

2023年12月，在夺回市场青睐的压力日益增大的情况下，赛诺菲为投资者举办了一次研发活动，吹捧了12项管道资产，这些资产可能在未来几年达到轰动地位。

Nine of these investigational drugs are under its innovative medicines and vaccines unit, each of which has the potential to hit peak sales of $2.15 billion to $5.4 billion, according to Sanofi. These include its multiple sclerosis hopeful tolebrutinib and its asthma assets rilzabrutinib and lunsekimig, as well as developmental vaccines for respiratory syncyrial virus, acne and extraintestinal pathogenic Escherichia coli..

据赛诺菲称，其中9种研究药物隶属于其创新药物和疫苗部门，每种药物都有可能达到21.5亿至54亿美元的峰值销售额。这些包括其多发性硬化症希望托莱鲁替尼和哮喘资产利扎鲁替尼和lunsekimig，以及针对呼吸道合胞病毒、痤疮和肠外致病性大肠杆菌的开发疫苗。。

In addition to its potential blockbusters, Sanofi revealed a campaign to increase its pipeline momentum with the goal of 50% growth in Phase III trials between 2023 and 2025. The company is also targeting almost 20 regulatory filings and 25 mid- to late-stage readouts in the next two years.

除了其潜在的重磅炸弹之外，赛诺菲还透露了一项旨在增加其管道动力的运动，目标是在2023年至2025年之间的三期试验中实现50%的增长。该公司还计划在未来两年内提交近20份监管文件和25份中后期读数。

Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

特里斯坦·马纳拉克（TristanManalac）是一位独立的科学作家，总部位于菲律宾大马尼拉。在LinkedIn上联系他，或发电子邮件给他tristan@tristanmanalac.com或tristan.manalac@biospace.com.